Context Therapeutics Inc. (CNTX)
(Real Time Quote from BATS)
$1.08 USD
+0.08 (8.03%)
Updated Oct 3, 2025 03:08 PM ET
4-Sell of 5 4
D Value D Growth D Momentum F VGM
Fundamental Charts
About Price to Cash Flow
The Price to Cash Flow ratio or P/CF is price divided by its cash flow per share. It's another great way to determine whether a company is undervalued or overvalued with the denominator being cash flow. One of the reasons why some investors prefer the P/CF ratio over the P/E ratio is because the net income of the cash flow portion rightly adds depreciation and amortization back in since these are not cash expenditures. In contrast, the net income that goes into the earnings portion of the P/E ratio does not add these in, thus artificially reducing the income and skewing the P/E ratio. Like the P/E ratio, a lower number is considered better. A value under 20 is generally considered good.
CNTX 1.08 +0.08(8.03%)
Will CNTX be a Portfolio Killer in October?
Zacks Investment Research is releasing its prediction for CNTX based on the 1-3 month trading system that more than doubles the S&P 500.
Zacks News for CNTX
Bet on These 5 Top-Ranked Stocks With Rising P/E
Zacks.com featured highlights include Context Therapeutics, Blue Bird, Dycom Industries and Leidos
CNTX: What are Zacks experts saying now?
Zacks Private Portfolio Services
Bet on 4 Top-Ranked Stocks With Rising P/E for Solid Gains
Other News for CNTX
CNTX rises 7.23% on October 2, leaving the technical picture intact
Context Therapeutics (CNTX) Receives "Overweight" Rating from Cantor Fitzgerald | ...
NR7 appears for CNTX after 0.11% move
Context Therapeutics initiated with an Overweight at Cantor Fitzgerald
Context Therapeutics initiated with bullish view at Cantor Fitzgerald, here's why